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TO THE EDITOR
Hidradenitis suppurativa (HS; OMIM1
42690) is a chronic inflammatory skin
disease that presents with nodules,
cysts, and abscesses in apocrine gland–-
bearing sites. It affects 1% of Europeans
and is primarily thought to be a disease
of follicular occlusion (Alikhan et al.,
2009). Associated factors include smok-
ing (B90%), obesity (475%), and
infection (Alikhan et al., 2009). HS
may segregate as an autosomal domi-
nant trait, and heterozygous mutations
in the g-secretase genes NCSTN, PSE-
NEN, and PSEN1 have recently been
reported in a small number of kindreds
(Wang et al., 2010; Li et al., 2011;
Liu et al., 2011; Pink et al., 2011).
We previously identified mutations in
NCSTN and PSENEN in two of seven
multiplex HS pedigrees. In contrast to
previous studies, which have predomi-
nantly focussed on the identification of
mutations in multiplex kindreds, the
aim of this study was to determine the
prevalence of mutations in each of
these genes among a large cohort of
subjects sequentially recruited from a
tertiary referral HS clinic. We per-
formed mutational analysis of NCSTN,
PSENEN, and PSEN1 by direct sequen-
cing of all coding regions and assess-
ment of large-scale deletions and
duplications by multiplex ligation phos-
phorylation assay (MLPA).
In all, 48 individuals with HS (diag-
nostic criteria from Von der Werth
et al., 2000) were sequentially con-
sented and recruited from our tertiary
referral clinic. The study was conducted
in accordance with the Declaration of
Helsinki Principles and approved by the
East London REC2 (09/H0704/50). Po-
pulation data are shown in Supplemen-
tary Table S1 online. The cohort was of
mixed ethnicity, the average body mass
index (BMI) was 31.1 (clinically obese),
69% reported a smoking history, and
the average Sartorius score (Sartorius
et al., 2003) was 49.9. A total of 20
(42%) patients reported a family history
of HS, 19 consistent with autosomal
dominant inheritance.
The DNA was extracted from venous
blood or saliva. All coding regions and
associated splice sites ofNCSTN, PSEN1,
and PSENEN were amplified by PCR,
using exon flanking intronic primers and
Sanger sequenced in all 48 patients. In
three subjects we identified heterozy-
gous DNA changes in NCSTN (Supple-
mentary Table S2 online), a missense
substitution (NCSTN c.553G4A, p.As-
p185Asn), and two single-base substitu-
tions located within 10bp of donor
splice junctions (NCSTN c.996þ 7G4A
and NCSTN c.1101þ 10A4G). To our
knowledge these variants have not pre-
viously been reported and none were
observed in dbSNP, 1,000 genomes, or
in 400 European controls. All 48 patients
were assessed for whole gene/exon
deletions and duplications in NCSTN,
PSENEN, and PSEN1 using MLPA (Sup-
plementary Methods online; Hills et al.,
2010). No genomic deletions or duplica-
tions were detected.
The heterozygous missense variant in
exon 5 of NCSTN (c.553G4A, p.As-
p185Asn) was identified in a 45-year-
old female (patient HS-01; Supplemen-
tary Table S2 online, Figure 1). The
missense variant is predicted to lead to
the substitution of an evolutionary con-
served aspartic acid residue with an
asparagine residue. A heterozygous
substitution of the conserved seventh
base of intron 8 of NCSTN (c.996þ
7G4A) was identified in a 38-year-old
female (patient HS-02 Supplementary
Table S2 online, Figure 1). Computa-
tional splice site analysis (https://splice.
uwo.ca) predicts this substitution to
have a detrimental effect on splicing.
NCSTN mRNA expression levels were
significantly lower than wild-type con-
trols, suggesting that the mutant tran-
script is subject to nonsense-mediated
decay (Supplementary Methods and
Supplementary Figure S1 online). A
third heterozygous variant was detected
in the donor splice site of NCSTN exon
9 (c.1101þ 10A4G) in a 24-year-old
male (patient HS-03; Supplementary
Table S2 online, Figure 1). Computa-
tional splice site analysis suggests that
this mutation is unlikely to have a signi-
ficant effect on splicing. Indeed, no
aberrant transcripts were detected (via
reverse transcriptase–PCR and sequen-
cing of the full-lengthNCSTN transcript,
Supplementary Figures S2 and S3 on-
line) and NCSTN mRNA expression
level was within the range of wild-type
controls (data not shown). The potential
pathogenicity of this variant is therefore
unclear and it may represent a rare vari-
ant unlinked to HS in this individual.
The two individuals with likely
pathogenic variants in NCSTN had
chronic, severe disease (Sartorius scores
of 56 and 160, respectively) comprising
painful nodules, cysts, abscesses, sinus
tracts, and scarring, involving at least
the axillae, groin, and buttocks (see
Supplementary Table S2 online). Their
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Abbreviations: BMI, body mass index; HS, hidradenitis suppurativa; MLPA, multiplex ligation
phosphorylation assay
disease started at the age of 13 and 35
years, respectively. They had a raised
BMI (38 and 37) and were both current
smokers. Both reported a history of type
II diabetes, neither had acne vulgaris,
and there was no history of inflamma-
tory bowel disease or other neutrophilic
dermatoses. The only effective treat-
ment option was surgical resection (see
Supplementary Table S2 online). Inter-
estingly, neither of these individuals
reported a family history of HS or any
associated conditions.
g-Secretase is an endoprotease com-
plex involved in the intramembranous
cleavage of numerous type-1 transmem-
brane proteins. To date, mutations have
been reported in three of the six genes
encoding proteins integral to the com-
plex (eight in NCSTN, three in PSENEN,
and one in PSEN1, Figure 2) (De Strooper
et al., 1999; Wang et al., 2010; Li et al.,
2011; Liu et al., 2011; Pink et al., 2011).
All but one of these mutations were
observed in multiplex kindreds, whereas
the HS cohort presented here is repre-
sentative of patients recruited from a
tertiary referral clinic (only 42% of
patients reported a family history). Our
data suggest that NCSTN, PSEN1, and
PSENEN are only responsible for a small
proportion of HS cases (o7%), and this
figure may be lower in the general
disease population given the phenotypic
severity of the cohort studied.
Of the 14 potential g-secretase mu-
tations now reported in HS, 2 are
nonsense mutations, 6 result in frame-
shifts, 4 in altered splicing, and 2 are
missense mutations. The pattern of
mutations suggests that loss-of-function
of components of the g-secretase com-
plex underlies the disease. Interestingly,
the NCSTN missense mutation reported
here (p.Asp185Asn) and the previously
reported p.Pro211Arg (Li et al., 2011)
are both located within the ectodomain
of NCSTN (Figure 2). These observa-
tions support a key functional role for
this domain within the g-secretase
complex and a critical role in HS
pathogenesis. It is currently difficult to
draw robust genotype–phenotype cor-
relations; however, the clinical pheno-
type of all reported mutation-positive
cases is severe and extensive.
In summary, we examined the g-
secretase genes NCSTN, PSENEN, and
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Figure 1. Three individuals with variants in NCSTN (HS-01, HS-02, and HS-03). (a) Patient HS-01.
Inflammatory nodules, abscesses, and scarring in the sub-mammary region. Arrow indicates the
NCSTN c.553 G4A variant, a heterozygous substitution in exon 5 of NCSTN (Genbank accession
number: NM_015331). (b) Patient HS-02. Inflammatory nodules and extensive scarring in the axilla.
Arrow indicates the NCSTN c.996þ 7 G4A variant, a heterozygous substitution of the seventh
base of the donor splice site within intron 8 of NCSTN. (c) Patient HS-03. Inflammatory nodules,
sinus tracts, and scarring in the groin. Arrow indicates the NCSTN c.1101þ 10 A4G variant, a
heterozygous substitution of the tenth base of the donor splice site within intron 9 of NCSTN.
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Figure 2. The location of all reported mutations within the c-secretase complex in HS. Mutations are
represented as stars. Both of the missense variants reported to date (p.Asp185Asn (patient HS-01) and the
previously reported p.Pro211Arg (Li et al., 2011)) are located within the ectodomain of nicastrin.
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PSEN1 for mutations in 48 individuals
with HS and identified three variants in
coding regions and splice sites of
NCSTN. To our knowledge these var-
iants are previously unreported. We
present evidence consistent with patho-
genicity of two of these alleles, adding
to the spectrum of described mutations
in this gene. Neither individual in
whom mutations were identified re-
ported a family history of HS demon-
strating the importance of NCSTN in
sporadic disease. These data confirm
that germline mutations of g-secretase
are confined to a minority of subjects
who develop HS and suggest that
additional and as yet unknown genes
predispose to the development of this
distressing disorder.
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Increased p63 Phosphorylation Marks Early Transition of
Epidermal Stem Cells to Progenitors
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TO THE EDITOR
The mammalian epidermis is maintained
by epithelial stem cells (SCs) capable of
self-renewal and differentiation (Fuchs,
2009). Although the transcription factor
p63 is critical for the proliferative
potential of epithelial SCs (Senoo et al.,
2007), the molecular events underlying
their transition to more differentiated
progenitors remain largely unknown.
Technical challenges in distinguishing
SCs from transit-amplifying (TA) cells,
early progeny of SCs (Watt, 2001),
complicate such analyses and impede
development of new strategies to im-
prove SC quality for therapeutic trans-
plantation and SC-directed gene therapy.
A current model dictates that SCs in
the interfollicular epidermis are located
in the basal layer, whereas TA cells are
found in both the basal and suprabasal
layers (Watt, 2001; Fuchs, 2008). As
epidermal SCs express relatively high
levels of p63 (p63hi) in culture (Pellegrini
et al., 2001; Senoo et al., 2007), we first
investigated whether p63hi cells were
restricted to the epidermal basal layer.
To identify the basal layer, we used
integrin b4 (Radoja et al., 2006). Un-
expectedly, we found p63hi cells in both
basal and suprabasal layers in adult
human epidermis (Figure 1a and b),
suggesting that high p63 expression is
not restricted to SCs. Because the
decrease in p63 expression accom-
panying epidermal cell differentiation
appears linked to phosphorylation and
consequent targeting for proteasome-
mediated degradation (Westfall et al.,
2005), we next asked whether initiation
of SC differentiation is accompanied by
an increase in p63 phosphorylation.
Abbreviations: CK14, cytokeratin-14; HPEK, human primary epidermal keratinocyte; SC, stem cell;
TA, transit amplifying
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